Celiac.com 07/08/2013 - Right now, the only way for doctors to distinguish between the complicated and uncomplicated forms of celiac disease is to use invasive methods.
The research team included Greetje J Tack, Roy LJ van Wanrooij, B Mary E Von Blomberg, Hedayat Amini, Veerle MH Coupe, Petra Bonnet, Chris JJ Mulder, and Marco WJ Schreurs. They are variously affiliated with the Departments of Epidemiology and Biostatistics, Gastroenterology and Hepatology, and Pathology of VU University Medical Centre in Amsterdam, The Netherlands, and with the Department of Immunology, Erasmus MC at theUniversity Medical Centre in Rotterdam, The Netherlands.
The team's cohort study looked at the possible use of new testing methods, including IL-6, IL-8, IL-17, IL-22, sCD25, sCD27, granzyme-B, sMICA and sCTLA-4 in patients diagnosed with active celiac disease, celiac disease following a gluten-free diet, Refractory celiac disease (RCD) types I and II, and enteropathy associated T-cell lymphoma (EATL).
The results showed elevated levels of the pro-inflammatory IL-8, IL-17 and sCD25 in both active celiac disease and RCDI-II. In addition, patients with RCDII showed higher serum levels of soluble granzyme-B and IL-6 compared with active celiac disease patients.
They did not find any differences between RCDI and active celiac disease, or between RCDI and RCDII. However, they did find that EATL patients had higher IL-6 levels compared with all other groups.
This study document a specific series of serum parameters that show that RCDII and EATL have distinct immunological features compared with uncomplicated celiac disease and RCDI. This new method of distinguishing uncomplicated and complicated forms of celiac disease might promote the development of non-invasive procedures in the future.